Analytical Data
-
Gene name
IL-36RN
- Application
-
Alternative Names
IL1HY1; IL36RN; IL36Ra; IL1RP3; IL1L1; IL1F5; Interleukin 1 Family, Member 5; Interleukin-1 HY1; IL-1 Related Protein 3; Interleukin 36 Receptor Antagonist
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
> 97% as determined by SDS-PAGE.
-
Uniprot
Q9QYY1
-
Expression Region
Met1~Asp156
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-36RN, or Interleukin-36 receptor antagonist, is a protein that plays a crucial role in regulating the immune response, particularly within the IL-36 cytokine family. This family includes IL-36α, IL-36β, and IL-36γ, which are pro-inflammatory cytokines involved in various inflammatory skin diseases, such as psoriasis and dermatitis. IL-36RN functions as a natural inhibitor, counteracting the effects of these pro-inflammatory cytokines by binding to their receptor and preventing their action. The imbalance between IL-36 and IL-36RN has been implicated in the pathogenesis of several autoimmune disorders, making it a critical focus for therapeutic intervention. Research into recombinant forms of IL-36RN aims to explore its potential as a therapeutic agent, providing insights into its structural properties and functional capabilities. Understanding its role in inflammation and immune regulation can lead to novel treatments for chronic inflammatory conditions, underscoring the importance of IL-36RN in both basic immunology and clinical applications. Furthermore, the development of recombinant IL-36RN can facilitate investigations into its mechanisms of action, paving the way for targeted therapies that could alleviate symptoms in affected patients. Such studies are vital, as they not only enhance our understanding of immune regulation but also contribute to the advancement of individualized medicine strategies in treating inflammatory diseases.
